Checkpoints and beyond - immunotherapy in colorectal cancer

Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this revie...

Full description

Saved in:
Bibliographic Details
Main Authors: Gutting, Tobias (Author) , Burgermeister, Elke (Author) , Härtel, Nicolai (Author) , Ebert, Matthias (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: Seminars in cancer biology
Year: 2018, Volume: 55, Pages: 78-89
ISSN:1096-3650
DOI:10.1016/j.semcancer.2018.04.003
Online Access:Verlag, Volltext: https://doi.org/10.1016/j.semcancer.2018.04.003
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1044579X17302687
Get full text
Author Notes:Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert

MARC

LEADER 00000caa a2200000 c 4500
001 1666323063
003 DE-627
005 20220816161536.0
007 cr uuu---uuuuu
008 190527r20192018xx |||||o 00| ||eng c
024 7 |a 10.1016/j.semcancer.2018.04.003  |2 doi 
035 |a (DE-627)1666323063 
035 |a (DE-599)KXP1666323063 
035 |a (OCoLC)1341225375 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gutting, Tobias  |d 1982-  |e VerfasserIn  |0 (DE-588)1165090708  |0 (DE-627)1029277370  |0 (DE-576)510243819  |4 aut 
245 1 0 |a Checkpoints and beyond - immunotherapy in colorectal cancer  |c Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert 
264 1 |c 2019 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 30 April 2018 
500 |a Gesehen am 27.05.2019 
520 |a Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhibitors, interleukin treatment and adoptive cell transfer (dendritic cells/cytokine induced killer cells, tumor infiltrating lymphocytes, chimeric antigen receptor cells, T cell receptor transfer) in pre-clinical models and clinical trials. We intensively examine approaches to overcome low immunogenicity by combination of different therapies and address future strategies of therapy as well as the need of predictive factors in this emerging field of precision medicine. 
534 |c 2018 
650 4 |a Immunotherapy 
650 4 |a Adoptive cell transfer 
650 4 |a Checkpoint inhibitor 
650 4 |a Colorectal cancer 
650 4 |a Immunosuppressive niche 
700 1 |a Burgermeister, Elke  |d 1968-  |e VerfasserIn  |0 (DE-588)173413455  |0 (DE-627)704732858  |0 (DE-576)184247551  |4 aut 
700 1 |a Härtel, Nicolai  |d 1977-  |e VerfasserIn  |0 (DE-588)129912913  |0 (DE-627)483650609  |0 (DE-576)297899821  |4 aut 
700 1 |a Ebert, Matthias  |d 1968-  |e VerfasserIn  |0 (DE-588)1030133522  |0 (DE-627)734827083  |0 (DE-576)377938432  |4 aut 
773 0 8 |i Enthalten in  |t Seminars in cancer biology  |d London : Academic Press, 1995  |g 55(2019), Seite 78-89  |h Online-Ressource  |w (DE-627)268128448  |w (DE-600)1471735-9  |w (DE-576)264423526  |x 1096-3650  |7 nnas  |a Checkpoints and beyond - immunotherapy in colorectal cancer 
773 1 8 |g volume:55  |g year:2019  |g pages:78-89  |g extent:12  |a Checkpoints and beyond - immunotherapy in colorectal cancer 
856 4 0 |u https://doi.org/10.1016/j.semcancer.2018.04.003  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1044579X17302687  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190527 
993 |a Article 
994 |a 2019 
998 |g 1030133522  |a Ebert, Matthias  |m 1030133522:Ebert, Matthias  |d 60000  |d 61100  |e 60000PE1030133522  |e 61100PE1030133522  |k 0/60000/  |k 1/60000/61100/  |p 4  |y j 
998 |g 129912913  |a Härtel, Nicolai  |m 129912913:Härtel, Nicolai  |d 60000  |d 61100  |e 60000PH129912913  |e 61100PH129912913  |k 0/60000/  |k 1/60000/61100/  |p 3 
998 |g 173413455  |a Burgermeister, Elke  |m 173413455:Burgermeister, Elke  |d 60000  |d 61100  |e 60000PB173413455  |e 61100PB173413455  |k 0/60000/  |k 1/60000/61100/  |p 2 
998 |g 1165090708  |a Gutting, Tobias  |m 1165090708:Gutting, Tobias  |d 60000  |d 61100  |e 60000PG1165090708  |e 61100PG1165090708  |k 0/60000/  |k 1/60000/61100/  |p 1  |x j 
999 |a KXP-PPN1666323063  |e 3479748945 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"disp":"Checkpoints and beyond - immunotherapy in colorectal cancerSeminars in cancer biology","physDesc":[{"extent":"Online-Ressource"}],"recId":"268128448","note":["Gesehen am 21.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"title":[{"title_sort":"Seminars in cancer biology","title":"Seminars in cancer biology"}],"part":{"pages":"78-89","year":"2019","volume":"55","text":"55(2019), Seite 78-89","extent":"12"},"id":{"zdb":["1471735-9"],"issn":["1096-3650"],"eki":["268128448"]},"pubHistory":["Nachgewiesen 6.1995 -"],"origin":[{"publisherPlace":"London","dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisher":"Academic Press"}]}],"person":[{"family":"Gutting","role":"aut","given":"Tobias","display":"Gutting, Tobias"},{"role":"aut","given":"Elke","family":"Burgermeister","display":"Burgermeister, Elke"},{"display":"Härtel, Nicolai","role":"aut","given":"Nicolai","family":"Härtel"},{"family":"Ebert","given":"Matthias","role":"aut","display":"Ebert, Matthias"}],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"note":["Available online 30 April 2018","Gesehen am 27.05.2019"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Checkpoints and beyond - immunotherapy in colorectal cancer","title_sort":"Checkpoints and beyond - immunotherapy in colorectal cancer"}],"physDesc":[{"extent":"12 S."}],"recId":"1666323063","name":{"displayForm":["Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert"]},"id":{"doi":["10.1016/j.semcancer.2018.04.003"],"eki":["1666323063"]}} 
SRT |a GUTTINGTOBCHECKPOINT2019